MLL Rearrangement clinical trials at UCSF

1 research study open to eligible people

MLL rearrangement is a change in a gene that can cause some types of leukemia. UCSF is studying ziftomenib given with standard drugs to check safety and side effects in people with relapsed or refractory acute myeloid leukemia. The studies also measure whether the treatment reduces leukemia cells.

Showing trials for

  • Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

    open to eligible people ages 18 years and up

    The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

    San Francisco, California and other locations

Our lead scientists for MLL Rearrangement research studies include .

Last updated: